NASDAQ:BXRX - Baudax Bio Stock Price Target and Predictions

  • Consensus Rating: N/A
  • Consensus Price Target: $0.00
  • Forecasted Upside: -100.00 %
  • Number of Analysts: 0
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$0.64
▼ -0.03 (-4.50%)

This chart shows the closing price for BXRX by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Baudax Bio Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for BXRX and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for BXRX

Analyst Price Target is $0.00
▼ -100.00% Downside Potential
This price target is based on 0 analysts offering 12 month price targets for Baudax Bio in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $0.64.

This chart shows the closing price for BXRX for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is N/A

The current consensus among 0 polled investment analysts is to n/a stock in Baudax Bio. This rating has held steady since April 2021, when it changed from a Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart

  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/30/2020
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/29/2020
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/28/2020
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/26/2020
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/24/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/24/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/23/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/23/2021

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/15/2020JMP SecuritiesInitiated CoverageOutperform$13.00High
5/11/2020OppenheimerLower Price TargetOutperform$16.00 ➝ $14.00Low
2/21/2020Piper SandlerBoost Price Target$11.00 ➝ $14.00Low
1/21/2020OppenheimerReiterated RatingBuy$12.00High
11/22/2019Janney Montgomery ScottInitiated CoverageBuy$12.00Low
11/22/2019Piper Jaffray CompaniesInitiated CoverageOverweight$12.00Low
(Data available from 7/23/2016 forward)
Baudax Bio logo
Baudax Bio, Inc., a pharmaceutical company, develops and commercializes products for hospital and other acute care settings. The company offers ANJESO (meloxicam) injection for the management of moderate to severe pain, alone or in combination with non-NSAID analgesics. Its products under development includes BX1000, an intermediate-acting neuromuscular blocking agent (NMBA) that is in phase I clinical trial; BX2000, an ultrashort-acting NMBA, which is in pre-clinical trial; and BX3000, an NMBA reversal agent, which is under pre-clinical trial, as well as Dex-IN, a proprietary intranasal formulation of dexmedetomidine, which is under phase II clinical trial. The company was incorporated in 2019 and is based in Malvern, Pennsylvania.
Read More

Today's Range

Now: $0.64
Low: $0.63
High: $0.69

50 Day Range

MA: $0.77
Low: $0.60
High: $0.92

52 Week Range

Now: $0.64
Low: $0.57
High: $3.94

Volume

691,463 shs

Average Volume

3,647,615 shs

Market Capitalization

$53.60 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.27

Frequently Asked Questions

What sell-side analysts currently cover shares of Baudax Bio?

The following sell-side analysts have issued stock ratings on Baudax Bio in the last twelve months: Zacks Investment Research.
View the latest analyst ratings for BXRX.

What is the current price target for Baudax Bio?

0 Wall Street analysts have set twelve-month price targets for Baudax Bio in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for Baudax Bio in the next year.
View the latest price targets for BXRX.

What is the current consensus analyst rating for Baudax Bio?

Baudax Bio currently has from Wall Street analysts. The stock has a consensus analyst rating of "N/A."
View the latest ratings for BXRX.

What other companies compete with Baudax Bio?

How do I contact Baudax Bio's investor relations team?

Baudax Bio's physical mailing address is 490 LAPP ROAD, MALVERN PA, 19355. The company's listed phone number is 484-395-2440 and its investor relations email address is [email protected] The official website for Baudax Bio is www.baudaxbio.com.